– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los datos preliminares se esperan para el segundo trimestre de 2025 –
Posted: 2025-03-08 07:56:00
Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeñaGlobe NewsWire News Distribution Service
Press Release: Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024
- Details
- Written by Globe NewsWire Press Releases
- Category: Globe NewsWire News Distribution Service
– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los datos preliminares se esperan para el segundo trimestre de 2025 –
Posted: 2025-03-08 07:56:00
Listen to this article. Speaker link opens in a new window.
Related Bing News Search Results
Press Release: Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024 - Newscast
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data ... - WOODTV.com
Tue, 27 May 2025 06:00:00 GMT - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline ... - OzarksFirst.com
Tue, 27 May 2025 06:00:00 GMT - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly ... - KTLA
Wed, 07 May 2025 05:00:00 GMT - Data to be reviewed during a Key Opinion Leader webinar Featuring Dr. Manuel Hidalgo Medina and Dr. Mike Pishvaian on Wednesday May 7 th, 2025 at 0800 US EDT - ROCKVILLE, Md., May 07, 2025 ...Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in ... - KRQE NEWS 13
Wed, 07 May 2025 05:00:00 GMT - Data to be reviewed during a Key Opinion Leader webinar Featuring Dr. Manuel Hidalgo Medina and Dr. Mike Pishvaian on Wednesday May 7 th, 2025 at 0800 US EDT - ROCKVILLE, Md., May 07, 2025 ...Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in ... - WAVY.com
Wed, 07 May 2025 05:00:00 GMT - Data to be reviewed during a Key Opinion Leader webinar Featuring Dr. Manuel Hidalgo Medina and Dr. Mike Pishvaian on Wednesday May 7 th, 2025 at 0800 US EDT - ROCKVILLE, Md., May 07, 2025 ...
Related Product Search/Búsqueda de productos relacionados
